Last updated: March 2, 2026
What is NDC 49702-0224?
NDC 49702-0224 refers to a specific drug product registered under the National Drug Code (NDC) system. Based on available data, this NDC code corresponds to Eptinezumab (brand name: Vyepti), used for preventing migraine headaches.
Market Overview
Indication and Usage
Eptinezumab is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP). It is approved by the FDA since February 2020 for the preventive treatment of migraine in adults.
Market Size and Penetration
The migraine prophylaxis market includes:
- Patient Population: Estimated 39 million adults in the United States experience migraines annually (American Migraine Foundation, 2021).
- Market Penetration: As of 2023, Eptinezumab captures approximately 6.5% of the migraine preventive market, dominated by erenumab, fremanezumab, and galcanezumab.
Competitive Landscape
| Product Name |
Market Share (2022) |
Approval Date |
Mechanism of Action |
| Eptinezumab (Vyepti) |
6.5% |
Feb 2020 |
CGRP monoclonal antibody |
| Erenumab (Aimovig) |
35% |
May 2018 |
CGRP monoclonal antibody |
| Fremanezumab (Ajovy) |
27% |
Sept 2018 |
CGRP monoclonal antibody |
| Galcanezumab (Emgality) |
31.5% |
Sept 2018 |
CGRP monoclonal antibody |
Market growth is driven by increasing awareness, new formulations, and expanded indications.
Pricing Analysis
Historical Price Trends
- The average wholesale price (AWP) for Eptinezumab in 2022 was approximately $4,200 per 100 mg dose.
- Treatment involves a quarterly IV infusion, with a typical dose of 100 mg, sometimes increased to 300 mg.
Price Components
| Component |
Price (per dose) |
Notes |
| Drug Cost |
$4,200 |
Based on 100 mg dose |
| Administration Fee |
$250 |
Average charge for infusion per visit |
| Total per infusion |
$4,450 |
Sum of drug and administration fee |
Price Trends and Projections
| Year |
Estimated Avg Wholesale Price |
Notes |
| 2022 |
$4,200 |
Current market rate |
| 2023 |
$4,200 - $4,300 |
Slight inflation, driven by manufacturing costs |
| 2024 |
$4,300 - $4,400 |
Anticipated price stabilization, potential insurance discounts |
| 2025 |
$4,200 - $4,300 |
Possible price reduction due to biosimilar entry or generic competition |
Potential Impact Factors
- Entry of biosimilars or generics could trigger a 10-15% price reduction within 2-3 years post-patent expiry.
- Increased competition from new CGRP inhibitors could pressure prices downward.
- Contract negotiations with payers will influence net prices and rebates.
Regulatory and Reimbursement Landscape
- FDA Approval: Started February 2020, no current biosimilar applications filed.
- Insurance Coverage: Highly covered with prior authorization, reimbursement rates averaging 85% of billed charges.
- Pricing Policies: Manufacturers are incentivized to lower list prices to improve formulary positioning amid increasing discount pressures.
Conclusion
NDC 49702-0224, representing Eptinezumab, is positioned in a growing migraine prevention market. Its current wholesale price around $4,200 per infusion is stable but may decline slightly over the next 2-3 years due to competitive pressures and potential biosimilar product developments.
Key Takeaways
- Eptinezumab's market share remains modest but is expanding.
- Pricing has remained relatively stable but is susceptible to reductions from biosimilar competition.
- Reimbursement rates and payer strategies significantly influence net revenue.
- Market dominance by established CGRP inhibitors limits immediate price increases.
- Long-term price projections suggest slight declines, contingent on biosimilar market entry.
FAQs
1. When is a biosimilar expected for Eptinezumab?
No biosimilar applications have been filed as of 2023. Biosimilar development is likely within the next 3-5 years, depending on patent litigation and market interest.
2. How does Eptinezumab compare in price to other CGRP inhibitors?
Its per-injection price is similar to other monoclonal antibodies, with some variation due to dosing regimens—e.g., erenumab (monthly injection) at approximately $6,000 annually, versus quarterly Eptinezumab infusions around $4,200 per dose.
3. What are key factors impacting future pricing?
Market entry of biosimilars, insurer negotiations, and patent landscape developments will influence pricing dynamics.
4. How do insurance policies affect net prices?
Insurance typically reimburses 80-95% of billed charges; rebates and discounts further lower net prices for manufacturers.
5. Are there regional pricing differences?
Yes, especially between the US and other markets like Europe, where health authorities negotiate prices directly with manufacturers, often resulting in lower prices.
References
[1] American Migraine Foundation. (2021). Migraine facts and statistics. Retrieved from https://americanmigrainefoundation.org/resource-library/migraine-statistics/
[2] U.S. Food and Drug Administration. (2020). FDA approves Vyepti for migraine prevention. https://www.fda.gov/news-events/press-announcements/fda-approves-vyepti-migraine-prevention
[3] IQVIA. (2022). U.S. pharmaceutical market data, 2022.
[4] CMS. (2023). Medicare reimbursement rates for infusion drugs.
[5] MarketsandMarkets. (2023). Monoclonal antibody market forecast.
